Puma Biotechnology, Inc.

NASDAQ: PBYI
$10.27
-$0.11 (-1.1%)
Closing price August 7, 2020
Puma Biotechnology shares made a handy gain early on Thursday after the company presented updated results from its Phase 2 Summit clinical trial of neratinib at the 2019 San Antonio Breast Cancer...
Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Tuesday's top analyst upgrades, downgrades and initiations included Apollo Global Management, BlackRock, Cloudflare, Green Plains, Microsoft, Oracle, Target and TJX Companies.
Puma Biotechnology shares jumped early Wednesday after FDA news about Puma’s breast cancer treatment. However, Puma shares quickly fell off from this FDA sugar high.
  Stocks were indicated to open lower on Monday after weekend news that sounds like a China trade deal is not on the way very soon. Investors have been forced to see numerous waves of selling in...
General Electric, Encana Energy, Puma Biotechnology, and Kraft Heinz all posted new 52-week lows Friday.
  Stocks were indicated to open higher on China trade deal hopes and after a stronger nonfarm payrolls report. While the stock market has bounced handily from the lows at the end of October,...
Puma Biotechnology shares were climbing on Tuesday after the company announced that it expects a positive outcome in Europe.
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
The world of biotech can be a rags-to-riches story for companies that build up a drug candidate and secure FDA approval for that drug. And the larger the drug target group is, the more exciting it...
The top analyst upgrades, downgrades and other research calls from Thursday include Albermarle, American Airlines, Ellie Mae, Johnson & Johnson, Mallinckrodt, Mylan, NetApp and Southwest Airlines.
Puma Biotechnology saw its shares take a dive on Wednesday following regulatory events in Europe for its breast cancer treatment.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
Puma Biotechnology, Inc. (NASDAQ: PBYI) saw its shares touch a multiyear high on Tuesday after the firm reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the...
Stocks were indicated marginally lower on Tuesday, but the major equity indexes remain just under all-time highs. The bull market may now be well over eight years old, but investors keep proving that...